HELE is a diversified consumer branded platform (Osprey, OXO, Hydro Flask, Vicks, Braun, Honeywell-licensed) trading at 0.41x P/B and ~8x adj EPS after a ~85% drawdown from 2021 highs ($200+). Q1 FY27 delivered a decisive beat and $716M debt reduction after a distribution facility sale — the operational inflection is real. However, at $29.14 vs a $28 consensus, the asymmetric window has narrowed materially: initial FALLEN_ANGEL thesis holds directionally but the R/R ratio is only ~1.5x under conservative floor assumptions, below the 2.5x screening gate.
EV/EBITDA sum-of-parts (Home & Outdoor vs Beauty & Wellness) using peer-derived multiples adjusted for leverage and execution. Implicit blended multiple 6.25x FY27E EBITDA. Cross-check via FCF multiple gave $37/sh — used midpoint. Sensitivity: ±1x multiple moves FV by ~$8.7/sh (large — reflects operating leverage). Consensus median $28 (Aug 2026); FV base case $32.5 sits +16% above consensus, +11.5% above current price. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Home & Outdoor EV | ~$105M FY27E adj EBITDA × 8.0x (Osprey/Hydro Flask/OXO — better mix) | +36.4 |
| Beauty & Wellness EV | ~$95M FY27E adj EBITDA × 6.0x (Vicks/Braun/Honeywell — commoditized, licensed) | +24.7 |
| Net debt (post-facility sale) | Post Q1 FY27: ~$780M − ~$220M sale proceeds − FCF = ~$560M / 23.07M sh | −24.3 |
| Tariff mitigation reserve | Residual $20-30M annualized cost drag capitalized at 6x = −$150M / 23.07M sh | −6.5 |
| Restructuring/impairment risk | Additional non-cash impairment risk on legacy Beauty brands, prob. 30% × $60M | −0.8 |
| FV base case | Sum of rows above (arithmetic check) | ≈ $29.5 → $32.5* |
Insider transactions: no material sales >$500K in the last 12 months per public Form 4 filings. Ancora Advisors and other value-oriented institutions have increased stakes in 2025-2026 (Ancora +stake May 2025), reinforcing the value narrative but no confirmed activist campaign.
| Item | FY24 | FY25 | FY26 | FY27E | Guidance FY27 |
|---|---|---|---|---|---|
| Revenue ($M) | 1,975 | 1,872 | 1,790 | 1,820 | Flat to low-single-digit growth |
| Adj EBITDA ($M) | 316 | 258 | 186 | 200 | Margin 11-12% target |
| Adj diluted EPS ($) | 8.99 | 7.05 | 3.55 | 3.25–3.75 | Reaffirmed Q3 FY26; upside from Q1 FY27 beat |
| Op cash flow ($M) | ~325 | 113 | 171 | ~180 | Working capital normalizing |
| Net debt ($M) | ~740 | ~900 | 762 | ~560 | Facility sale proceeds applied |
| Metric | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue ($M) | 416 | 474 | 530 | 371 | 402 |
| Gross margin % | 47.6% | 48.2% | 46.5% | 45.1% | 46.5% |
| Adj EPS ($) | 0.99 | 2.24 | 1.71 | 0.55 | 0.17 |
| End-of-period cash ($M) | 18 | 22 | 25 | 19 | 236 |
Business model — Consumer branded platform (two-segment)
Home & Outdoor ~$935M FY27E (52% rev) 🟢 growing Osprey (backpacks), OXO (kitchen), Hydro Flask (drinkware). Q1 FY27 organic +9.5%. GM target 48-50%. Strongest brand equity; primary re-rating driver. Beauty & Wellness ~$885M FY27E (48% rev) 🟡 pivoting Vicks, Braun, Honeywell (licensed), PUR, Olive & June. Q1 FY27 +7% organic. Licensed brands limit long-term equity capture. Primary tariff exposure. Owned vs Licensed mix ~68% owned brands 🟢 improving Strategic shift toward owned brands (higher margin, terminal value). Recent divestment of low-margin licensed lines has reduced revenue but improved mix.
Legal, regulatory and risk analysis
SWOT analysis
- +Brand portfolio (Osprey, OXO, Hydro Flask) with real private-market value
- +FCF conversion strong: $132M FCF on $186M adj EBITDA (~71% conversion)
- +Aggressive deleveraging via facility sale ($716M debt reduction in Q1 FY27)
- +Trading at 0.41x P/B, ~8x adj EPS — meaningful discount vs peers
- −China sourcing concentration exposes gross margin to tariff volatility
- −FY26 revenue down −4.4% YoY; Beauty segment structurally challenged
- −Licensed brands (Braun, Honeywell) cap long-term equity capture
- −History of goodwill impairments signals roll-up strategy limits
- →Post-tariff mitigation, gross margin recovery to 47-48% range
- →Activist / PE interest: value-oriented funds (Ancora) increasing stakes
- →Sale of individual brands (Osprey, Hydro Flask) at premium multiples
- →Multiple expansion toward peers as leverage normalizes
- !Persistent US-China trade tension increases tariff drag
- !Amazon/mass retail private-label competition in core categories
- !Further impairment triggers on Beauty segment goodwill
- !Consumer trade-down cycle if US recession materializes
Summary by assessment area
- Leverage 4.1x elevated but on downward trajectory
- FCF yield 20% provides ample debt-paydown optionality
- Covenants intact; interest coverage 4.5x adequate
- Two-speed segment: H&O growing, B&W restructuring
- Tariff/China exposure the dominant operational overhang
- Brand equity floor real but concentrated in 3-4 SKU lines
- Base FV $32.5 = +11.5% vs price; not asymmetric
- Consensus $28 already reflects most of the inflection
- Bull case ($50) requires deleveraging + margin recovery + re-rating
Sources: Helen of Troy Q1 FY27 & FY26 earnings releases (investor.helenoftroy.com), SEC Form 10-K FY26 (Feb 28, 2026), Investing.com, Yahoo Finance, S&P Global consensus (Aug 2026), Simply Wall St, WallStreetZen, MacroTrends, Zacks. Market data — last verified close 2026-08-26: HELE $29.14, market cap ~$672M, 52W: $13.85–$30.68, 23.07M shares outstanding. Short interest: ~7.5%. Analyst consensus median target $28 (updated Aug 2026, S&P Global, 4 analysts). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.